Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer

Despite modest clinical improvement with anti-vascular endothelial growth factor antibody (AVA) therapy in ovarian cancer, adaptive resistance is ubiquitous and additional options are limited. A dependence on glutamine metabolism, via the enzyme glutaminase (GLS), is a known mechanism of adaptive re...

Descripción completa

Detalles Bibliográficos
Autores principales: Glassman, Deanna, Kim, Mark S., Spradlin, Meredith, Badal, Sunil, Taki, Mana, Bhattacharya, Pratip, Dutta, Prasanta, Kingsley, Charles V., Foster, Katherine I., Animasahun, Olamide, Jeon, Jin Heon, Achreja, Abhinav, Jayaraman, Anusha, Kumar, Praveen, Nenwani, Minal, Wuchu, Fulei, Bayraktar, Emine, Wu, Yutuan, Stur, Elaine, Mangala, Lingegowda, Lee, Sanghoon, Yap, Timothy A., Westin, Shannon N., Eberlin, Livia S., Nagrath, Deepak, Sood, Anil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941132/
https://www.ncbi.nlm.nih.gov/pubmed/36824283
http://dx.doi.org/10.1016/j.isci.2023.106020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941132/
https://www.ncbi.nlm.nih.gov/pubmed/36824283
http://dx.doi.org/10.1016/j.isci.2023.106020

Ejemplares similares